Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connective Portfolio Management LLC

Connective Portfolio Management LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 97.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 630 shares of the biopharmaceutical company’s stock after selling 25,000 shares during the quarter. Connective Portfolio Management LLC’s holdings in Regeneron Pharmaceuticals were worth $449,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $37,000. Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $39,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $42,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $703.43 on Thursday. The business has a 50 day simple moving average of $746.43 and a 200-day simple moving average of $956.18. The company has a market capitalization of $77.30 billion, a P/E ratio of 17.41, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,032.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.